Clinical Trials

Do you or your child have a lung disease? This study will investigate the genes involved in the breathing process and in the development of lung diseases such as asthma or sarcoidosis to improve understanding of the role they play. To participate in this study, you or your child must be between 2 and 90 years old. This study is located in Bethesda, Maryland, at the NIH Clinical Center.

DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 24-27 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.

The objective of this study is to investigate the mechanisms of respiratory functional and respiratory motor responses to the scES as an important step toward the long-term goal of developing effective evidence-based rehabilitation strategies for patients with SCI. The central hypothesis is that scES raises the excitability of motor networks for respiration resulting in amplified use-dependent neural plasticity in response to the respiratory training. The rationale for the proposed study is to justify the development of a new direction in respiratory rehabilitation by using respiratory training in combination with electrical spinal cord stimulation.

The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.

Are you in need of a heart or lung transplant or have you had one in the past 3 months? Have you undergone a lung or heart transplant in the past 3 months or are you a candidate for heart or lung transplant? Some people with advanced heart and lung disease have heart and lung transplants but these new organs are often rejected. When this happens, patients must have repeated biopsies, which are invasive and expensive. Researchers in this clinical study want to see if a blood test can predict organ rejection and take the place of biopsies. To participate, you must be 18 to 80 years old and be a candidate for heart or lung transplant or have had a heart or lung transplant no more than three months ago. The study is taking place in Bethesda, Maryland, at the NIH Clinical Center, as well as in Baltimore, Maryland, and Falls Church, Virginia.